Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19 AI128913)
City of Hope PDDV Program COH04
Received: 5 July 2020
Accepted: 2 November 2020
First Online: 30 November 2020
: Funds were allocated to Don J. Diamond by the City of Hope (COH) for research that resulted in the development of multi-antigenic SARS-CoV-2 vaccine using a synthetic poxvirus platform discussed in this publication. While unknown whether publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to COH. COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. Don J. Diamond is a co-inventor on two patent applications that were submitted by COH to the USPTO prior to submission of this manuscript for consideration at Nature Communications. Both patent applications are in provisional status and have not yet converted to utility applications that have an official USPTO application number. One patent application covers the design and construction of the synthetic MVA platform, and another patent application covers the development of a COVID-19 vaccine. Felix Wussow is a co-inventor of the same two provisional patent applications that apply to Don J. Diamond. All remaining authors that have not been referenced above have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the interpretation of the article.